RTOG
RADIATION THERAPY ONCOLOGY GROUP

REIMBURSEMENT & CASE CREDIT SUMMARY

RTOG #	Study	CTEP Credit	DCP Credit	CTEP Funding	DCP Funding	Corporate Funding	Total
0413	PBI:NSABP B-39	1.0	0.0	$2,000	$0	$0	$2,000
0433	NCIC:BONE METS	0.0	1.0	$0	$2,000	$0	$2,000
0436	PH III ESOPH RT/CHEM	1.0	0.5	$2,000	$1,000	$2,500	$5,500
0514	H/N TISSUE/SPEC**	1.0	0.0	$0	$0	$0	$0
0521	AS/3DCRT/IMRT:PRO	1.5	0.0	$2,000	$0	$1,000	$3,000
0524	BLADDER:CHEM + RT	1.0	0.0	$2,000	$0	$0	$2,000
0526	BRACHY:PROSTATE	1.0	0.0	$2,000	$0	$0	$2,000
0534	PHASE III:PELVIC	1.0	0.5	$3,000	$1,000	$0	$4,000
	Includes $1,000 per pt. from CTEP Complexity Trials Program. DCP credit & funding only for first 400 pts. on QOL study.						
0537	PH III ELECSTIM XEROSTOMIA	0.0	1.0	$0	$2,000	$0	$2,000
0538	LUNG-CALGB 30610	1.0	0.0	$2,000	$0	$0	$2,000
0539	MENINGIOMA: IMRT*	1.0	0.0	$2,000	$0	ARRA $3700	$5700
0612	MARKER:PROS:DNA	0.5	0.0	$1,000	$0	$0	$1,000
0614	WBRT +/- NAMENDA	0.0	1.0	$0	$2,000	$0	$2,000
0617	PHASE III:LUNG	1.0	0.5	$2,000	$1,000	$1,000	$4,000
0618	SBRT:NSCLC	2.0	0.0	$2,000	$0	$0	$2,000
0621	PROSTATE:3DCRT	1.0	0.0	$2,000	$0	$0	$2,000
0622	PHASE II:PROS:IGRT	1.0	0.0	$2,000	$0	$0	$2,000
0627	DASATINIB/GLIOBLA	1.0	0.0	$2,000	$0	$500	$2,500
0630	PHASE II:IGRT SARCOMA	1.0	0.5	$2,000	$1,000	$0	$3,000
0631	PH II/III RADIOSURG FOR SPINE METS	0.0	1.0	$0	$2,000	$0	$2,000
0712	TUR, CHEMORT-BLADDER	1.0	0.0	$2,000	$0	$0	$2,000
0724	PH III STAGE I/II CERVIX	1.0	0.5	$2,000	$1,000	$0	$3,000
0813	SBRT OPERABLE NSCLC	1.0	0.0	$2,000	$0	$0	$2,000
0815	PH III LOW INTERMED RISK PROSTATE	1.0	0.5	$2,000	$1,000	$0	$3,000
	DCP credit & funding for first 400 pts. on QOL study. Now closed to QoL entries.						
0822	LOCALLY ADV RECTAL	1.0	0.0	$2,000	$0	$0	$2,000
0825	RT/TMZ/BEV OR PLACEBO	1.0	0.5	$2,000	$1,000	$3,000	$6,000
	Payments are administered in stages – see below for benchmarks						
0828	VISIONTREE QOL FORMS**	0.5	0.0	$0	$0	$0	$0
0831	PH III CIALIS FOR ED	0.0	1.0	$0	$2,000	$0	$2,000
0834	CATNON Study	1.0	0.5	$2,000	$1,000	$2,000	$5,000
	Payments are administered in stages. Please see RTOG and CTSU web pages for benchmarks. QOL for first 352 pts.						
0837	PH II Double Blind Placebo Controlled Glioblastoma	1.0	0.0	$2,000	$0	$0	$2,000
	Screening 0.5 credit & $500; Randomization 0.5 credit & $1,500. Additional $$ for sites participating in ACRIN 6689 imaging component.						
0839	PH IIR ± Panitumumab for LA NSCLC	1.0	0	$2,000	$0	$1,000	$3,000
0841	Depression Screening	0.0	1.0	$0	$2,000	$0	$2,000
0848	PH III Pancreas	1.5	0.5	$2,000	$1,000	$0	$4,000*
	Includes $1,000 per patient from the CTEP Complexity Trials Program. DCP credit and funding awarded upon submission of FA & PR forms: $400 & 0.1 credit at baseline; $150 & 0.1 credit at end of therapy and at 9, 12 & 24 months from start of therapy.						
0912	PH II IMRT + Paclitaxel/Pazopanib - Thyroid	1.0	0.0	$2,000	$0	$1,000	$3,000
0913	PH I/II RT + RA001 + TMZ Glioblastoma	1.0	0.0	$2,000	$0	$1500	$3500
0915	PH IIR SBRT INOP NSCLC	1.0	0.0	$2,000	$0	$0	$2,000
0920	PH III INTERMED H&N	1.0	0.5	$2,000	$1,000	$0	$3,000
	DCP credit & funding for first 316 pts. on QOL study.						
0921	PH II Post Op IMRT Endometrial Cancer	1.0	0.0	$2,000	$0	$0	$2,000
0924	Ph III AD with High Dose RT for Prostate	1.0	*0.5	$2,000	*$1,000	$0	$3,000
	*for first 460 patients that participate in QoL portion of the study. Baseline submission of FA, HP, QF & QL = $400 & 0.3 credits; Follow-up submission of FA, HP, QF & QL.= $200 each of next 3 time point						

RTOG
RADIATION THERAPY ONCOLOGY GROUP

REIMBURSEMENT & CASE CREDIT SUMMARY

RTOG #	Study	CTEP Credit	DCP Credit	CTEP Funding	DCP Funding	Corporate Funding	Total
0925	Low Risk Glioma	0	1.0	0	$2,000	0	$2,000
	Screening 0.5 credit & $500; Registration to Intervention arm 0.5 credit & $1,500						
0926	PH II Bladder RT + CIS	1.0	0.0	$2,000	$0	$0	$2,000
0929	PH I/IIR TEMZ + ABT-888 Glioblastoma	1.0	0.0	$2,000	$0	$1,000	$3,000
0933	PH II Hippocampal Avoidance	0.0	1.0	$0	*$2,000	$0	$2,000
	*Payment of $1,400 for submission of baseline forms (I1, CS, FA & PQ); Follow-up submission of CS, FA & PQ = $200 at mos. 2, 4 & 6						
0938	PH II Hypofractionated RT for Prostate	0	1.0	0	*$2,000	$0	$2,000
	*Payment of $1,400 for submission of baseline forms (I1, FA, QF, SA); Follow-up submission of FA, QF & SA= $200 at yrs. 1, 2 & 5						
0937	PH II/III Lung PCI vs PCI + RT	1.0	0.0	$2,000	$0	$0	$2,000
1005	PH III Whole Breast Hypo Concurrent Boost	1.0	*0.5	$2,000	*$1,000	$0	$3,000
	*DCP funding/credit for first 592 pts. on QOL study. Baseline submission of BQ & QP = $200 & 0.1 credits; Follow-up submission of BQ at end of RT, 1 mo. & 6 mo. = $200 & 0.1 credit; ; Follow-up submission of BQ & QP at 12 mos. = $200 & 0.1 credit; Follow-up submission of BQ at 24 mos. = $200 & 0.1 credit; Follow-up submission of BQ & QP at 36 mos. = $200 & 0.1 credit.						
1008	PH IIR RT ± Chemo for High-Risk Salivary	1.0	*0.5	$2,000	*$1,000	$0	$3,000
	*DCP funding/credit for first 120 pts. on QOL study. Baseline submission of FA, QP, HP, L4 & QL = $400 & 0.2 credits; Follow-up submission of FA, QP, HP, L4 & QL at 3, 12, & 24 mos.= $200 & 0.1 credits at each time point .						
1010	PH III Trastuzumab for HER2+ Esophagus	1.0	*0.3	$2,000	*$600	$1,000	$3,600
	0.5 credit & $500 at screening; 0.5 credit & $2,500 ($1,500 CTEP+ $1,000 corporate funds) at randomization. *DCP funding/credit for first 160 pts. on QOL study. Baseline, 1 yr. & 2 yr. submission of FA & HP = $200 & 0.1 credit at each time point.						
1012	PH II Manuka Honey for Esophagitis	0	1.0	0	*$2,000	0	$2,000
	**Payment of $1,400 for submission of baseline forms (I1, QL, QP & DP); $300 at 4 & 12 wks. with submission of all required QoL data.						
1014	PH II Partial Breast Re-Irradiation	1.0	0.0	$2,000	$0	$0	$2,000
1016	PH III RT/Cetuximab for HPV+ Oropharynx	1.0	*0.5	$2,000	*$1,000*	$500	**$3,500
	Screening 0.5 credit & $500; Randomization 0.5 credit & $2,000. *DCP funding/credit for first 706 patients enrolled in QOL study: Baseline QoL $300; BRASS $100; Follow-up QoL $120 each time point. ****HIV positive patients receive $4,500 in additional case reimbursement for a total of $8,000.**						
1021	PH III SBRT for Lung (ACOSOG-Z4099)	1.0	0.0	$2,000	$0	$0	$2,000
1102	PH I Ganitumab for Pancreas	1.0	0.0	$2,000	$0	$0	$2,000
1106	PH II Adaptive RT FDG-PET/CT for NSCLC	2.5	0.0	*$5,000	$0	$0	$5,000
	*Includes $3,000 NCI Enhanced Reimbursement. No additional funding for submission of biospecimen materials. Additional funding is available from ACRIN for the FDG PET/CT and FMISO PET/CT components. See link on RTOG website 1106 study page.						
1112	Ph III, HCC Sorafenib + SBRT	1.0	0.0	$2,000	$0	$0	$2,000
1114	PH II CNS Lymphoma	2.5	**0.5	*$5,000	**$1,000	$0	$6,000
	*Includes $3,000 NCI Enhanced Reimbursement. No additional funding for submission of biospecimen materials. **Payment & credit only for patients participating n Neurocog/QoL study. Baseline + Tx QoL (QL & CS Forms) $400 + 0.5 credits; follow-up QoL $50						
1115	PH III High-Risk Prostate – TAK-700	1.0	*0.5	$2,000	*$1,000	**$4,500	$7,500
	*DCP credit & funding for first 410 patients enrolled for QOL. **$2,500 at registration; $1,000 after receipt of 12 and 30 mo. follow-ups.						
1119	PH IIR Brain Mets fr Breast CA - Lapatinib	1.0	0.0	*$5,000	$0	$0	$5,000
	*Includes $3,000 NCI PH IIR Reimbursement. No additional funding for submission of biospecimen materials.						
1122	PH II BEV +/- AMG-486 Recurrent GBM/GS	2.5	0.0	*$5,000	$0	$0	$5,000
	*Includes $3,000 NCI Enhanced Reimbursement. No additional funding for submission of biospecimen materials.						
1203	PH IIR IMRT for Post-Op Cervix (TIME-C)	0	1.0	0	*$2,000	0	$2,000
	*0.4 credit & $1,400 at registration; 0.1 credit & $100 with submission of FA at each time point.						
1205	PH IIR Bev +/- Re-Irradiation for Recurrent GBM	1.0	0.0	*$5,000	$0	$0	$5,000
	*Includes $3,000 NCI PH IIR Reimbursement. No additional funding for submission of biospecimen materials.						
1216	PH II/III Surg/RT + Chen + Cetux	1.0	*0.5	$2,000	*$1,000	$0	$3,000
	*DCP credit & funding for first 475 patients enrolled for QOL. Payment & credit for QOL will be associated with data timepoints.						

- CTEP Credit/funding = Awarded by the NCI Cancer Therapy Evaluation Program for treatment-related endpoints.
- DCP Credit/funding = Awarded by the NCI Division of Cancer Prevention for symptom management and quality of life endpoints.
- Both CTEP and DCP credits are used to calculate member accrual.
- Data must be submitted in a timely fashion and the case must be eligible in order to qualify for per case reimbursement.

See next page for Biospecimen Reimbursement Schedule.

BIOSPECIMEN SUBMISSION REIMBURSEMENT SCHEDULE		
SPECIMEN	**FORM CODE**	**REIMBURSEMENT TO SITES** *(per specimen based on protocol-specified time points)*
Serum	JS	$50
Plasma	JP	$50
Whole blood	JW	$50
Urine	JU	$50
CSF	JC	$250
Unstained slides (min 10, max 20)	JN	$100
Tissue block	JB	$200
Punch	JH	$150
Fresh frozen tissue	JF	$300
Saliva	JL	$50
Buccal lavage or other swab	JR	$50
For most studies RTOG will reimburse submitting institutions after confirmation from the RTOG Biospecimen Resource that appropriate useable materials have been received. It may take several months for that determination to be completed. Studies that do not receive additional reimbursement for biospecimens are noted on that study's reimbursement schedule.		

RTOG 0825 Payment & Credit Schedule		
Submission Requirement	**Amount**	**Credit**
1st Step Registration – A1		0.5
2nd Step Registration – A2	$500	
3rd Step Registration – A3	$1,500	0.05
1st Treatment Summary Form – TF	$2,000	
1st Follow-Up Form – F1	$1,000	
Neurocognitive Evaluation Baseline – CS*	$500	0.05
Neurocognitive Evaluation Year 2 or Early Termination – CS*	$500	
*These payments apply only to those cases for which informed consent has been obtained to participate in the QoL portion of the trial.		